AEM vs ALTO

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

ALTO's deterministic health scores reveal significant concerns: a Piotroski F-Score of 2/9 indicates weak financial health, and the absence of an Altman Z-Score raises distress risk concerns. Despite this, the stock trades at a discount to its Graham Number ($3.38) and intrinsic value ($1.12), suggesting potential undervaluation. The recent earnings surprise history is volatile but highly positive in the most recent quarters, with a 75% Q/Q EPS growth and 149% YoY EPS growth. Strong price momentum—253% 1-year return and 294.9% 6-month return—reflects market optimism, supported by a strong-buy analyst consensus. However, the company's negative revenue growth (-1.90% YoY) and minimal profitability (1.45% profit margin) remain critical red flags. Price trades at a 37.9% premium to fair value estimate ($3.38), limiting near-term upside from a valuation perspective.